On March 26, 2020, ReCode Therapeutics, Inc. announced the completion of an all-stock merger with TranscripTx, Inc and, immediately thereafter, the closing of an oversubscribed $80 million Series A financing round. OrbiMed Advisors LLC and Colt Ventures co-led the round, with participation from MPM Capital, Vida Ventures LLC, Hunt Technology Ventures, L.P., and Osage University Partners.

ReCode will use the proceeds to continue the preclinical development of its lead programs in primary ciliary dyskinesia and cystic fibrosis. The company expects to file an Investigational New Drug Application for both programs in 2021. In addition, ReCode will advance its proprietary non-viral lipid nanoparticle delivery platform for organ-specific delivery of RNA therapies and gene editing components.

Wilson Sonsini Goodrich & Rosati represented TranscripTx in the merger and represents the post-transaction ReCode. The Wilson Sonsini team included partners Kenneth Clark, Vern Norviel, Michael Coke, Myra Sutanto Shen, Ali Alemozafar, and Alex Key and associates Kimball Smith, Alex Weber, Alison Renner, Heather Diles, and Jason Chan.  

For more information, please see ReCode’s press release.